We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current COV market cap is 28.37M. The company's latest EPS is CAD -0.1808 and P/E is -6.36.
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 34M | 25.8M | 30.12M | 18.63M | 26.6M |
| Operating Income | -8.25M | -6.09M | -1.68M | -9.53M | -4.53M |
| Net Income | -9.14M | -6.95M | 23.48M | -9.66M | -4.46M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 39.61M | 34.7M | 40.58M | 30.38M | 24.9M |
| Total Liabilities | 24.68M | 25.59M | 7.21M | 6.15M | 6.11M |
| Total Equity | 14.93M | 9.11M | 33.37M | 24.23M | 18.79M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -2.83M | -4.03M | 621k | -7.99M | -3.18M |
| Investing | -7.1M | -370k | -278k | -843k | -1.45M |
| Financing | 13.98M | -1.75M | -8.25M | -2.19M | -2.16M |
| Market Cap | 28.37M |
| Price to Earnings Ratio | -6.36 |
| Price to Sales Ratio | 1.07 |
| Price to Cash Ratio | 3.23 |
| Price to Book Ratio | 1.51 |
| Dividend Yield | - |
| Shares Outstanding | 24.67M |
| Average Volume (1 week) | 7.9k |
| Average Volume (1 Month) | 5.73k |
| 52 Week Change | -42.50% |
| 52 Week High | 2.14 |
| 52 Week Low | 0.96 |
| Spread (Intraday) | 0.05 (4.17%) |
| Company Name | Covalon Technologies Ltd |
| Address |
1660 tech avenue, unit 5 mississauga, ontario L4W 5S7 |
| Website | https://www.covalon.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
